Isomorphic Labs is the secretive AI life sciences startup spun out of Google DeepMind with the goal of solving all disease with AI-powered drug discovery.

Isomorphic Labs, Google’s artificial intelligence drug business, raised $600 million in its first external funding round, the company said on Monday.

Demis Hassabis, cofounder of DeepMind and 2024 Nobel Laureate, talks to Fortune about his AI drug discovery startup, Isomorphic Labs.

Isomorphic Labs, Google’s A.I. Drug Business, Raises $600 Million The company, which uses artificial intelligence to develop new treatments, now counts the venture capital firm Thrive Capital as ...

Isomorphic Labs will use the windfall to fund development of its AI drug design model, and is also looking to expand its team as it grows.

Isomorphic Labs, the AI drug-discovery platform that was spun out of Google's DeepMind in 2021, has raised external capital for the first time. The $600 ...

Isomorphic Labs raised $600 million in its first external funding round to boost its artificial-intelligence drug design pipeline across multiple therapeutic areas.

Isomorphic Labs Inc., a healthcare startup that spun out of Alphabet Inc. in 2021, today announced that it has closed a $600 million funding round. OpenAI backer Thrive Capital led the investment ...

Isomorphic Labs, a subsidiary of Alphabet Inc., said it entered into strategic research collaboration agreements with Novartis AG and Eli Lilly & Co.

Isomorphic Labs partners with Eli Lilly and Novartis, leveraging AI for drug discovery; deals worth $3B. Isomorphic receives $45M from Eli Lilly, $37.5M from Novartis for AI-driven medication ...

Just more than two years after launching within Alphabet, Isomorphic has inked two large pharma deals with Eli Lilly and Novartis with nearly $3 billion in combined deal value. | Just more than ...

Isomorphic Labs is the secretive AI life sciences startup spun out of Google DeepMind with the goal of solving all disease with AI-powered drug discovery.